RecruitingNot ApplicableNCT05093881

Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study

Sponsor

Pharmicell Co., Ltd.

Enrollment

100 participants

Start Date

Aug 24, 2021

Study Type

INTERVENTIONAL

Conditions

Alcoholic Cirrhosis

Summary

This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.

Eligibility

Inclusion Criteria2

Those who participated in PMC-P-07 clinical trials and received Cellgram-LC
Those who voluntarily agreed in writing to participate in this investigation

Exclusion Criteria1

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALCellgram-LC

Patients who had administered Cellgram-LC in PMC-P-07 study

Locations(11)

Soonchunhyang University Hospital

Bucheon-si, South Korea

Soonchunhyang University Hospital

Cheonan, South Korea

Gangwon National University Hospital

Chuncheon, South Korea

Hallym Univ. Medical Center

Chuncheon, South Korea

Gangneung Asan Hospital

Gangneung-si, South Korea

Eunpyeong St. Mary's Hospital

Seoul, South Korea

Korea University Anam Hospital

Seoul, South Korea

Seoul National University Hospital

Seoul, South Korea

Soonchunhyang University Hospital

Seoul, South Korea

Wonju Severance Christian Hospital

Wŏnju, South Korea

Yongin Severance Hospital

Yŏngin, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05093881

Related Trials

SAMe Trial for Patients With Alcoholic Cirrhosis

NCT042502592 locations

Optimized Remission in Alcohol-related Liver Cirrhosis

NCT068664961 location

Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis

NCT0468915211 locations